Trial Profile
An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Biocon
- 09 Feb 2022 Results of predictive and prognostic associations of different cancer stem cell markers in HPV-negative locally advanced HNSCC patients, by deriving pretreatment tumour tissues, published in the British Journal of Cancer
- 17 Sep 2020 Results (n=404) assessing prognostic and predictive association of biomarkers in HPV negative locally advanced HNSCC patients, published in the British Journal of Cancer
- 31 May 2020 Results (N=354), assessing the prognostic value of radiological extranodal extension for predicting outcomes, presented at the 56th Annual Meeting of the American Society of Clinical Oncology